Bing Yao, ArriVent Biopharma CEO
January 3, 2023 08:49 AM ESTUpdated 11:13 AM
Financing
Startups
China

Scoop: Bing Yao’s Ar­riVent lin­ing up $145M raise, af­ter $150M de­but in 2021

Kyle LaHucik

Senior Reporter

Bing Yao took his pre­vi­ous biotech through three key mile­stones: IPO, drug ap­proval and an M&A ex­it. Now, he’s lin­ing up an­oth­er round of fi­nanc­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times